戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  ozanimod 0.5 mg; and 11 [2.5%] who received interferon beta-1a).
2  ozanimod 0.5 mg; and 16 [3.6%] who received interferon beta-1a).
3 mpared with three (2%) patients treated with interferon beta 1a.
4 uzumab versus 85 (45%) patients treated with interferon beta 1a.
5 t for all therapies apart from intramuscular interferon beta-1a.
6  part of a clinical trial of natalizumab and interferon beta-1a.
7 o-controlled, multicenter phase III trial of interferon beta-1a.
8 se patients compared with those treated with interferon beta-1a.
9 rate of clinical relapses than intramuscular interferon beta-1a.
10 crelizumab and in 2.9% of those treated with interferon beta-1a.
11 crelizumab and in 0.2% of those treated with interferon beta-1a.
12 ng were higher with daclizumab HYP than with interferon beta-1a.
13 rophy in high risk CIS patients treated with interferon beta-1a.
14 ated a significantly lower relapse rate than interferon beta-1a.
15 bility after treatment with alemtuzumab than interferon beta-1a.
16 relapse rates and MRI outcomes compared with interferon beta-1a.
17 le sclerosis, as compared with intramuscular interferon beta-1a.
18 improved after alemtuzumab but not following interferon beta-1a.
19 ltiple sclerosis patients being treated with interferon-beta-1a.
20 rate was lower with daclizumab HYP than with interferon beta-1a (0.22 vs. 0.39; 45% lower rate with d
21      Adjusted ARRs were 0.35 (0.28-0.44) for interferon beta-1a, 0.18 (95% CI 0.14-0.24) for ozanimod
22 5% CI 43.2-60.7%) than patients treated with interferon beta-1a (15 of 66 patients, 27.2%, 17.2-41.4%
23 mod 1.0 mg or 0.5 mg or weekly intramuscular interferon beta-1a 30 mug.
24 mod 1.0 mg or 0.5 mg or weekly intramuscular interferon beta-1a 30 mug.
25 eeks was lower with daclizumab HYP than with interferon beta-1a (4.3 vs. 9.4; 54% lower number of les
26 ompared with 52 of 107 patients treated with interferon beta-1a (42.6%, 32.4-52.4%; hazard ratio [HR]
27  stratified by site, to receive subcutaneous interferon beta 1a 44 mug, intravenous alemtuzumab 12 mg
28 us alemtuzumab 12 mg per day or subcutaneous interferon beta 1a 44 mug.
29 andomly assigned in a 1:1:1 ratio to receive interferon beta-1a (44 mug subcutaneously three times pe
30                                              Interferon beta-1a, 6.0 million units (30 micrograms inv
31 gnificantly lower with ocrelizumab than with interferon beta-1a (9.1% vs. 13.6%; hazard ratio, 0.60;
32 eficial effects of alemtuzumab compared with interferon beta-1a across all analysed patient subsets,
33 usly at a dose of 150 mg every 4 weeks, with interferon beta-1a, administered intramuscularly at a do
34 e of relapse over a two-year period than was interferon beta-1a alone (0.34 vs. 0.75, P<0.001) and wi
35 eta-1a was significantly more effective than interferon beta-1a alone in patients with relapsing mult
36 with combination therapy and 29 percent with interferon beta-1a alone.
37                        Patients treated with interferon beta-1a also had significantly fewer exacerba
38 se of either 1.25 or 0.5 mg or intramuscular interferon beta-1a (an established therapy for multiple
39 187 (96%) of 195 patients randomly allocated interferon beta 1a and 376 (97%) of 386 patients randoml
40 202 (87%) of 231 patients randomly allocated interferon beta 1a and 426 (98%) of 436 patients randoml
41 kly intramuscular injections of 30 microg of interferon beta-1a and 190 were assigned to receive week
42  764 patients were randomly assigned: 386 to interferon beta-1a and 378 to glatiramer acetate.
43 vous system, developed during treatment with interferon beta-1a and a selective adhesion-molecule blo
44                                              Interferon beta-1a and glatiramer acetate are commonly p
45  There was no significant difference between interferon beta-1a and glatiramer acetate in the primary
46 d symptoms with treatment for MS, first with interferon beta-1a and then with glatiramer acetate, sug
47 gned to ozanimod 0.5 mg, and 441 assigned to interferon beta-1a) and 1138 (86.7%) completed 24 months
48 ion of disability compared with subcutaneous interferon beta-1a, and the mean expanded disability sta
49  however, in patients who initially received interferon beta-1a, ARR was lower after switching to fin
50 participants self-administered intramuscular interferon beta-1a as background anti-inflammatory treat
51 ose of 600 mg every 24 weeks or subcutaneous interferon beta-1a at a dose of 44 mug three times weekl
52                    Initiating treatment with interferon beta-1a at the time of a first demyelinating
53 ive of this work was to assess the effect of interferon beta-1a (Avonex) on the rate of development o
54 ious complications because MS drugs, such as interferon beta-1a, can worsen the course of SS.
55 rpose of this study was to determine whether interferon beta-1a could slow the progressive, irreversi
56 ecific for interleukin-10, as treatment with interferon-beta-1a did not result in accumulation of tra
57 that has demonstrated superior efficacy over interferon beta-1a for relapsing-remitting multiple scle
58                     40 (20%) patients in the interferon beta 1a group had sustained accumulation of d
59                  20 (11%) of patients in the interferon beta 1a group had sustained accumulation of d
60                     75 (40%) patients in the interferon beta 1a group relapsed (122 events) compared
61                    104 (51%) patients in the interferon beta 1a group relapsed (201 events) compared
62                     94 (47%) patients in the interferon beta 1a group were relapse-free at 2 years co
63 plan-Meier estimates, 59% of patients in the interferon beta 1a group were relapse-free at 2 years co
64 mpared with 134 [66%] of 202 patients in the interferon beta 1a group) that were mostly mild-moderate
65  adverse events compared with 12 (6%) in the interferon beta 1a group, and three (1%) had immune thro
66 e thrombocytopenia compared with none in the interferon beta 1a group.
67 nt-emergent adverse events was higher in the interferon beta-1a group (365 [83.0%] of 440 participant
68 mmon in the daclizumab HYP group than in the interferon beta-1a group (in 65% vs. 57% of the patients
69 ower than expected: 258 patients (126 in the interferon beta-1a group and 132 in the glatiramer aceta
70 tients in the placebo group, patients in the interferon beta-1a group had a relative reduction in the
71                     More participants in the interferon beta-1a group had treatment-emergent adverse
72 ple sclerosis was significantly lower in the interferon beta-1a group than in the placebo group (rate
73  in the ozanimod 0.5 mg group; and 36 in the interferon beta-1a group).
74 lizumab HYP group and in 10% of those in the interferon beta-1a group.
75                                              Interferon beta-1a had a significant beneficial impact i
76 cing lesions, although patients treated with interferon beta-1a had significantly fewer gadolinium-en
77                                    Pegylated interferon beta-1a has shown efficacy in a phase 3 trial
78 y and comparable safety of fingolimod versus interferon beta-1a (IFN beta-1a) in paediatric-onset mul
79 ertaken to determine whether combined use of interferon beta-1a (IFN) 30 mug intramuscularly weekly a
80 clerosis (SENTINEL) study, patients received interferon beta-1a (IFN-beta-1a) plus natalizumab 300 mg
81 nal changes in the biopharmaceutical product interferon beta-1a (IFN-beta-1a).
82    A systematic mutational analysis of human interferon-beta-1a (IFN-beta) was performed to identify
83                            We tested whether interferon-beta-1a (IFN-beta-1a), which increases CD73 s
84 monotherapy in AFFIRM or in combination with interferon beta-1a (IFNbeta) in SENTINEL.
85 .25, or 5 mg/day), placebo, or intramuscular interferon beta-1a (IFNbeta-1a IM) during the core studi
86 t benefits of fingolimod 0.5 or 1.25 mg over interferon beta-1a (IFNbeta-1a) in patients with relapsi
87                   To evaluate the effects of interferon beta-1a (IFNbeta-1a, 30 microg administered i
88 nter, phase III, placebo-controlled study of interferon beta-1a (IFNbeta-1a; AVONEX) in relapsing for
89 arison, SPMS subjects from the intramuscular interferon beta-1a (IM IFNbeta-1a) IMPACT study were als
90 fety of first-line alemtuzumab compared with interferon beta 1a in a phase 3 trial.
91  disability, comparing alemtuzumab 12 mg and interferon beta 1a in all patients who received at least
92 cacy and safety of alemtuzumab compared with interferon beta 1a in patients who have relapsed despite
93 nd disability worsening by 40% compared with interferon beta 1a in relapsing-remitting multiple scler
94 o-controlled clinical effectiveness trial of interferon beta 1a in the treatment of IPF.
95 and accumulation of disability compared with interferon beta-1a in a phase 2 trial.
96 od before randomization to receive continued interferon beta-1a in combination with 300 mg of nataliz
97 m the safety and efficacy of ozanimod versus interferon beta-1a in individuals with relapsing multipl
98 zumab reduced disease activity compared with interferon beta-1a in most of the analysed subgroups.
99 nd efficacy of ozanimod versus intramuscular interferon beta-1a in participants with relapsing multip
100  Efficacy of Natalizumab in Combination with Interferon Beta-1a in Patients with Relapsing Remitting
101  Efficacy of Natalizumab in Combination With Interferon Beta-1a in Patients With Relapsing-Remitting
102 e safe and effective alone and when added to interferon beta-1a in preliminary studies.
103 rt confirms previous reports that the use of interferon beta-1a in the course of misdiagnosed MS may
104 ibody, is proven to be more efficacious than interferon beta-1a in the treatment of relapsing-remitti
105 se rate was lower with ocrelizumab than with interferon beta-1a in trial 1 (0.16 vs. 0.29; 46% lower
106 n was 0.02 with ocrelizumab versus 0.29 with interferon beta-1a in trial 1 (94% lower number of lesio
107 ment) significantly favored ocrelizumab over interferon beta-1a in trial 2 (0.28 vs. 0.17, P=0.004) b
108 mdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a - in patients hospitalized with coron
109 me the fourth study of the beta interferons (interferon-beta-1a, in this case) to demonstrate a parti
110                  Intramuscular injections of interferon-beta-1a increased serum levels of interleukin
111                                              Interferon-beta-1a induced accumulation of interleukin-1
112                                              Interferon beta-1a is beneficial when initiated at the f
113  on natalizumab monotherapy >18 months, 6 on interferon beta-1a monotherapy >36 months, and 5 untreat
114  1.0 mg (n=447), ozanimod 0.5 mg (n=451), or interferon beta-1a (n=448).
115  interferon beta-1a, with rate ratios versus interferon beta-1a of 0.62 (95% CI 0.51-0.77; p<0.0001)
116  of the study was to determine the effect of interferon-beta-1a on the expression of interleukin-10,
117  within the brain were randomized to receive interferon beta-1a or placebo after initial treatment wi
118 weekly intramuscular injections of 30 microg interferon beta-1a or placebo.
119  fingolimod at a dosage of 0.5 or 1.25 mg/d, interferon beta-1a, or placebo.
120 tes of disease activity and progression than interferon beta-1a over a period of 96 weeks.
121 eks was 16% with daclizumab HYP and 20% with interferon beta-1a (P=0.16).
122 0 mg (rate ratio [RR] of 0.52 [0.41-0.66] vs interferon beta-1a; p<0.0001), and 0.24 (0.19-0.31) for
123  for ozanimod 0.5 mg (RR 0.69 [0.55-0.86] vs interferon beta-1a; p=0.0013).
124    At the 3-year point patients treated with interferon beta-1a showed a 50% less risk of CDMS.
125              In contrast, those treated with interferon beta-1a steadily accumulated disability.
126 uced compared with the previous 12 months of interferon beta-1a therapy (p<0.0001 for T2 lesions at b
127 randomly assigned 1171 patients who, despite interferon beta-1a therapy, had had at least one relapse
128 re randomised to receive 44 mug subcutaneous interferon beta-1a three times per week or 20 mg subcuta
129 olimod compared with the previous 12 months (interferon beta-1a to 0.5 mg fingolimod [n=167], 0.31 [9
130 s 0.22 [0.15-0.31], in months 13-24 p=0.049; interferon beta-1a to 1.25 mg fingolimod [n=174], 0.29 [
131                               Switching from interferon beta-1a to fingolimod led to enhanced efficac
132 tients to assess the effect of a change from interferon beta-1a to fingolimod, and to compare over 24
133         Compared with patients switched from interferon beta-1a to fingolimod, continuous treatment w
134 s compared with the group that switched from interferon beta-1a to fingolimod, we recorded lower ARRs
135  34.9% in the placebo group and 21.9% in the interferon beta-1a-treated group.
136 0 in placebo-treated patients versus 0.61 in interferon beta-1a-treated patients.
137 tively evaluated the effect of intramuscular interferon beta-1a treatment following the first demyeli
138 is of MS who developed symptoms of SS during interferon beta-1a treatment for MS; these symptoms were
139 enrolled in the Observational Study of Early Interferon beta-1a Treatment in High Risk Subjects after
140                                              Interferon beta-1a treatment produced a significant dela
141                                              Interferon beta 1a was given three-times per week and al
142                                              Interferon beta 1a was given three-times per week and al
143                         Natalizumab added to interferon beta-1a was significantly more effective than
144                                The effect of interferon-beta-1a was relatively specific for interleuk
145 ginally received 30 mug weekly intramuscular interferon beta-1a were randomly reassigned (1:1) to rec
146 n Relapsing MS Disease) study was to compare interferon beta-1a with glatiramer acetate in patients w
147 umab HYP showed efficacy superior to that of interferon beta-1a with regard to the annualized relapse
148 h ozanimod 0.5 mg, and 0.28 (0.23-0.32) with interferon beta-1a, with rate ratios versus interferon b

 
Page Top